152 related articles for article (PubMed ID: 17303774)
1. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study.
Mallat Z; Benessiano J; Simon T; Ederhy S; Sebella-Arguelles C; Cohen A; Huart V; Wareham NJ; Luben R; Khaw KT; Tedgui A; Boekholdt SM
Arterioscler Thromb Vasc Biol; 2007 May; 27(5):1177-83. PubMed ID: 17303774
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.
Boekholdt SM; Keller TT; Wareham NJ; Luben R; Bingham SA; Day NE; Sandhu MS; Jukema JW; Kastelein JJ; Hack CE; Khaw KT
Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):839-46. PubMed ID: 15692105
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris.
Kugiyama K; Ota Y; Sugiyama S; Kawano H; Doi H; Soejima H; Miyamoto S; Ogawa H; Takazoe K; Yasue H
Am J Cardiol; 2000 Oct; 86(7):718-22. PubMed ID: 11018189
[TBL] [Abstract][Full Text] [Related]
4. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes.
Mallat Z; Steg PG; Benessiano J; Tanguy ML; Fox KA; Collet JP; Dabbous OH; Henry P; Carruthers KF; Dauphin A; Arguelles CS; Masliah J; Hugel B; Montalescot G; Freyssinet JM; Asselain B; Tedgui A
J Am Coll Cardiol; 2005 Oct; 46(7):1249-57. PubMed ID: 16198839
[TBL] [Abstract][Full Text] [Related]
5. [Elevated serum secretory type II phospholipase A2 in patients with coronary heart disease].
Yu L; Jiang WB; Fu GS; Qin GM; Wang JH; Huang ZQ
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Sep; 34(9):812-5. PubMed ID: 17217690
[TBL] [Abstract][Full Text] [Related]
6. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events.
Tsimikas S; Mallat Z; Talmud PJ; Kastelein JJ; Wareham NJ; Sandhu MS; Miller ER; Benessiano J; Tedgui A; Witztum JL; Khaw KT; Boekholdt SM
J Am Coll Cardiol; 2010 Sep; 56(12):946-55. PubMed ID: 20828647
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Heiss G; Sharrett AR
Circulation; 2004 Feb; 109(7):837-42. PubMed ID: 14757686
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.
Ballantyne CM; Hoogeveen RC; Bang H; Coresh J; Folsom AR; Chambless LE; Myerson M; Wu KK; Sharrett AR; Boerwinkle E
Arch Intern Med; 2005 Nov; 165(21):2479-84. PubMed ID: 16314544
[TBL] [Abstract][Full Text] [Related]
9. CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up.
Hartford M; Wiklund O; Mattsson Hultén L; Perers E; Person A; Herlitz J; Hurt-Camejo E; Karlsson T; Caidahl K
Int J Cardiol; 2006 Mar; 108(1):55-62. PubMed ID: 16516698
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
Koenig W; Khuseyinova N; Löwel H; Trischler G; Meisinger C
Circulation; 2004 Oct; 110(14):1903-8. PubMed ID: 15451783
[TBL] [Abstract][Full Text] [Related]
11. PLA2G10 Gene Variants, sPLA2 Activity, and Coronary Heart Disease Risk.
Guardiola M; Exeter HJ; Perret C; Folkersen L; Van't Hooft F; Eriksson P; Franco-Cereceda A; Paulsson-Berne G; Palmen J; Li K; Cooper JA; Khaw KT; Mallat Z; Ninio E; Karabina SA; Humphries SE; Boekholdt SM; Holmes MV; Talmud PJ
Circ Cardiovasc Genet; 2015 Apr; 8(2):356-62. PubMed ID: 25583995
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women.
Rana JS; Arsenault BJ; Després JP; Côté M; Talmud PJ; Ninio E; Wouter Jukema J; Wareham NJ; Kastelein JJ; Khaw KT; Boekholdt SM
Eur Heart J; 2011 Feb; 32(3):336-44. PubMed ID: 19224930
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study.
Rana JS; Cote M; Després JP; Sandhu MS; Talmud PJ; Ninio E; Wareham NJ; Kastelein JJ; Zwinderman AH; Khaw KT; Boekholdt SM
Heart; 2009 Oct; 95(20):1682-7. PubMed ID: 19587389
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention.
Liu PY; Li YH; Tsai WC; Chao TH; Tsai LM; Wu HL; Chen JH
Eur Heart J; 2003 Oct; 24(20):1824-32. PubMed ID: 14563341
[TBL] [Abstract][Full Text] [Related]
15. IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study.
Boekholdt SM; Peters RJ; Hack CE; Day NE; Luben R; Bingham SA; Wareham NJ; Reitsma PH; Khaw KT
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1503-8. PubMed ID: 15178568
[TBL] [Abstract][Full Text] [Related]
16. Retinol-binding protein 4 and prediction of incident coronary events in healthy men and women.
Mallat Z; Simon T; Benessiano J; Clément K; Taleb S; Wareham NJ; Luben R; Khaw KT; Tedgui A; Boekholdt SM
J Clin Endocrinol Metab; 2009 Jan; 94(1):255-60. PubMed ID: 18854400
[TBL] [Abstract][Full Text] [Related]
17. Group IIA Secretory Phospholipase A
Akinkuolie AO; Lawler PR; Chu AY; Caulfield M; Mu J; Ding B; Nyberg F; Glynn RJ; Ridker PM; Hurt-Camejo E; Chasman DI; Mora S
Arterioscler Thromb Vasc Biol; 2019 Jun; 39(6):1182-1190. PubMed ID: 31070471
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.
van Capelleveen JC; Bernelot Moens SJ; Yang X; Kastelein JJP; Wareham NJ; Zwinderman AH; Stroes ESG; Witztum JL; Hovingh GK; Khaw KT; Boekholdt SM; Tsimikas S
Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1206-1212. PubMed ID: 28473441
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of phospholipase A2-IIA in patients with different types of malignancies: prognosis and association with inflammatory and coagulation biomarkers.
Menschikowski M; Hagelgans A; Schuler U; Froeschke S; Rosner A; Siegert G
Pathol Oncol Res; 2013 Oct; 19(4):839-46. PubMed ID: 23722320
[TBL] [Abstract][Full Text] [Related]
20. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease.
Kugiyama K; Ota Y; Takazoe K; Moriyama Y; Kawano H; Miyao Y; Sakamoto T; Soejima H; Ogawa H; Doi H; Sugiyama S; Yasue H
Circulation; 1999 Sep; 100(12):1280-4. PubMed ID: 10491371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
